Quick Answer
Janux Therapeutics, Inc. reported Diluted EPS of $1.83 per share (loss) for fiscal year 2025.
Janux Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$1.83 | -43.0% |
| 2024 | -$1.28 | +3.0% |
| 2023 | -$1.32 | +13.2% |
| 2022 | -$1.52 | -9.4% |
| 2021 | -$1.39 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.39 | +23.5% | +29.1% |
| June 30, 2025 | -$0.55 | -400.0% | -44.7% |
| March 31, 2025 | -$0.38 | -26.7% | +25.5% |
| September 30, 2024 | -$0.51 | -104.0% | -363.6% |
| June 30, 2024 | -$0.11 | +73.8% | +63.3% |
| March 31, 2024 | -$0.30 | +28.6% | -20.0% |
| September 30, 2023 | -$0.25 | +37.5% | +40.5% |
| June 30, 2023 | -$0.42 | -2.4% | +0.0% |
- Janux Therapeutics, Inc. showed a decrease of -43.0% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, Janux Therapeutics, Inc.’s diluted eps has declined by 31.7% (from $1.39 per share (loss) to $1.83 per share (loss)).
- The most recent figure is from Janux Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: